An observational study in Colorectal Cancer, sponsored by IFOM ETS - The AIRC Institute of Molecular Oncology. Recruiting at 13 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-24.
Sponsored by IFOM ETS - The AIRC Institute of Molecular Oncology · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 429 studies in Colorectal Neoplasms with a site in Italy — 103 open to participants now, 143 under way, 18 of them phase 3. Colorectal Neoplasms · Italy.
Among the 429 studies in Colorectal Neoplasms with a site in Italy, this one is the 32nd largest by planned enrollment of the 96 observational ones that give a count, is one of 29 that started in 2020, is one of 96 observational ones, reaches primary completion later than 40 of the 142 other live ones, and was the 296th registered.
6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →103 of the 429 studies in Colorectal Neoplasms with a site in Italy are open now. Recruiting first, the newest first:
Azienda USL Reggio Emilia - IRCCS · Sites in Italy
Ages 18+
Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis · Sites in Italy
Ages 18+
Blue Earth Diagnostics · Sites in Italy, Netherlands
Ages 18–79
EMD Serono Research & Development Institute, Inc. · Sites in Italy, United States, Argentina and 16 more countries
Ages 18+
Gruppo Oncologico Italia Meridionale · Sites in Italy
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
429 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 81 · Phase 2 155 · Phase 3 81 · Phase 4 3
First in 1988; this study’s year is marked. 29 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 250 across 1,444 observational studies indexed under Colorectal Neoplasms.
Median enrollment 215 across the 329 interventional studies, 258 across the 96 observational. Of the 228 that completed or were terminated, 99 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
213 of 429 have an industry lead sponsor. The 10 most frequent:
IFOM ETS - The AIRC Institute of Molecular Oncology is the lead sponsor of 7 studies on the registry; 5 are open to participants now.
IFOM ETS - The AIRC Institute of Molecular Oncology has 4 studies filed under Colorectal Neoplasms — fewer than ten, so there is no comparison to draw.
42 of the studies in Colorectal Neoplasms with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07792109Fondazione Policlinico Universitario Agostino Gemelli IRCCSImplementation Of A Telesurgery Program At A Referral Center For Robotic Surgery | 2026-11-30 |
| NCT02919644Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSVaccination With Autologous Dendritic Cells Loaded With Autologous Tumour Homogenate After Curative Resection for Stage IV Colorectal Cancer. | 2026-12 |
| NCT05789069HiFiBiO TherapeuticsA Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors | 2026-12 |
| NCT05205330Rottapharm BiotechVorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers | 2026-12 |
| NCT07116668SafeHeal IncSafeHeal Colovac Anastomosis Protection Device Evaluation Pivotal Study | 2026-12 |
Add all 42 to your calendar (.ics) → With an account.
Among the 429 studies in Colorectal Neoplasms with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
ALFAOMEGA-RETRÒ will be exploited to retrospectively collect clinical and imaging data and archival samples to be used for validation and correlative studies on markers discovered by cutting-edge translational projects within the AIRC5x1000 program "Insights into the evolving heterogeneity of colorectal cancer (CRC): from mechanism to therapies" (an ongoing multi-institutional research program).
ALFAOMEGA-RETRÒ, the retrospective "mirror" protocol of ALFAOMEGA (protocol n. IFOM-CPO003/2018/PO002), has been designed to build a retrospective collection of clinically annotated data and biological samples retrieved from colorectal cancer patients (CRC).
The repository will feed experimental precision research aimed at i) defining a new taxonomy of CRC based on evolutionary patterns (retrospectively assessed on patient's samples), ii) developing and evaluating innovative biomarker-specific therapeutic strategies derived from or together with ALFAOMEGA.
The following data and biological samples will be collected:
at least 500 colorectal cancer patients at any stage who cannot be reached for an informed consent
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stage-mixed cohort of at least 500 CRC patients that cannot be reached for informed consent (death or lost-to-follow-up)
Other: Observation
Retrospective Observation of standard clinical practice
Number of retrospectively recruited CRC cases
Number of retrospectively recruited CRC cases with complete matched clinical data, radio-imaging data and FFPE or frozen biological samples.
Time frame: 6 months
Number of new prognostic and predictive markers
Number of identified/validated new independent prognostic and predictive biomarkers
Time frame: 6 months
Biomarkers correlation with PFS
Correlation of new prognostic and predictive biomarkers with progression-free survival (PFS).
Time frame: 6 months
Biomarkers correlation with OS
Correlation of new prognostic and predictive biomarkers with overall survival (OS).
Time frame: 6 months
Not enrolling at this site.
Plan to share: Undecided
No publications or documents are linked to this record.
Started Oct 2020 (actual). Primary completion is estimated for Jun 2026, 68 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
IFOM ETS - The AIRC Institute of Molecular Oncology